RecruitingPhase 1NCT07401472

Study of BW-50218 in Healthy Participants

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered BW-50218 in Healthy Participants

Sponsor

Shanghai Argo Biopharmaceutical Co., Ltd.

Enrollment

60 participants

Start Date

Mar 12, 2026

Study Type

INTERVENTIONAL

Conditions

Healthy Participants Study

Summary

Phase 1, Single Ascending Dose Study of Subcutaneous BW-50218 in Healthy Participants

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called BW-50218 Injection and a drug called Saline (0.9% NaCl) for people with healthy participants study. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.